Challenges in Cardiovascular Therapy
Cardiovascular and anti-aging therapies remain too slow, costly, and imprecise, especially in conditions like HLHS where delayed interventions can have life-altering consequences.
Traditional approaches often focus on symptom management instead of root causes such as tissue degeneration and cellular aging. HeartQ is presented as an attempt to close that gap with QNN-guided insights and precision treatment planning.
Journey Behind HeartQ
Michelle L. Wu ties HeartQ to a family story involving a brother born with Hypoplastic Left Heart Syndrome, describing how that relationship shaped her determination to build solutions that improve and extend lives facing cardiovascular challenges.
The article connects that motivation with her interdisciplinary background in chemistry, biomedical engineering, applied mathematics, and quantum mechanics, alongside mentorship from UC Berkeley and MIT and graduate business study at Carnegie Mellon University.
HeartQ's Quantum-Driven Solution
HeartQ combines quantum-powered simulations with injectable nanobiometallic scaffolds intended for heart tissue regeneration and cellular rejuvenation.
HeartQ cites up to 95% intervention prediction accuracy, a 6x increase in solution speed, and literature-backed signals including a 42% improvement in heart tissue regeneration and a 25% increase in cellular metabolism.
As with TumorQ, patient security is framed as part of the core system through NEXQ's NIST-inspired encryption language.
Mission and Vision
HeartQ is presented as a long-view effort to merge regenerative medicine, longevity science, and quantum technology into a more hopeful cardiovascular future.
The article frames the work as both a tribute to people who inspire the mission and a commitment to privacy-conscious, precision-driven innovation.